AGENUS INC
Moat Score — Agenus Inc.
Total Moat Score
5 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Agenus holds patent protection around its Fc-enhanced CTLA-4 antibody (botensilimab) and its broader antibody discovery platform, representing genuine scientific differentiation, though this has not yet translated into an approved, commercially validated product. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a clinical-stage biotech with no significant commercial manufacturing scale, Agenus has no cost advantage and is a persistent net cash consumer funded through equity raises and periodic asset divestitures. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | With no approved product generating meaningful commercial revenue, Agenus has no pricing power today; any future pricing power would depend on demonstrated clinical differentiation in indications underserved by existing checkpoint inhibitors. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in antibody-based oncology drug development. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Because Agenus is targeting 'cold' tumor indications with few effective existing immunotherapy options, there is little incumbent therapy for oncologists and patients to switch away from, which lowers switching costs but also means Agenus must establish new treatment adoption rather than displace an entrenched competitor. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The specific niche of Fc-enhanced CTLA-4 combination therapy for immunotherapy-resistant solid tumors is narrow and could support efficient scale for an early, successful mover, but this remains hypothetical prior to regulatory approval and commercial validation. |